Anzol (Anastrozole)

Quick links

Choose a section

Quick links to important sections

Advertisements

Anzol (Anastrozole)

Advertisements
Advertisements

Overview of Anzol (Anastrozole)

Property Description
Active Ingredient Anastrozole
Form Oral Tablet
Pharmacological Class Non-steroidal Aromatase Inhibitor (AI)
General Purpose Estrogen synthesis suppression
Origin Synthetic compound

What Type of Medicine is Anzol (Anastrozole)?

Anzol is a prescription-only medication whose active ingredient, Anastrozole, is recognized as a potent Non-steroidal Aromatase Inhibitor (AI). This medicine is a synthetic, third-generation drug, exclusively supplied as a single-ingredient oral tablet, intended for internal use. Its classification places Anastrozole within the broader group of anti-estrogen agents. The compound is structurally recognized in pharmacological studies for its high selectivity and efficacy in enzyme binding.

Composition and Origin of Anzol

Anzol is a pharmaceutical product containing only the chemical substance Anastrozole as its active component, which is a key feature of this targeted therapy. Anastrozole is a triazole compound that is entirely synthetic in origin, manufactured chemically rather than being derived from biological sources. The finished oral formulation consists of the active substance combined with necessary solid pharmaceutical excipients, creating a tablet designed for systemic absorption. Although Anzol is a distinct trade name, it contains the same Anastrozole formulation as other prominent global brands.

General Purpose: Targeting Estrogen Synthesis

The overarching purpose of Anzol is to provide focused endocrine therapy by fundamentally reducing the amount of estrogen produced and circulating in the body. This specific action is achieved through highly selective aromatase enzyme inhibition, which is clinically recognized for creating a powerful hypoestrogenic state. By blocking the activity of the aromatase enzyme, the medicine effectively lowers the level of estrogen. The general utility of this medicine is therefore anchored in its ability to manage conditions where the presence of estrogen drives biological activity.

Regulatory References

  1. National Library of Medicine
Advertisements

What side effects are possible with Anzol (Anastrozole)?

Possible side effects and safety information

The safety profile of Anzol (Anastrozole) is officially documented by regulatory authorities, with adverse reactions categorized primarily by frequency and the body system affected. These classifications communicate the documented risks without providing clinical advice or usage instructions.

Frequency-Classified Adverse Reactions

The medicine's safety documentation uses standard frequency tiers. The most commonly reported side effects, classified as Very Common (ge 1/10), include hot flushes, asthenia (fatigue), headache, nausea, and arthralgia (joint pain). Reactions classified as Common (ge 1/100 to < 1/10) include musculoskeletal effects like osteoporosis and fractures, as well as depression, hypercholesterolaemia, and vaginal bleeding. The regulatory classification also lists effects as Uncommon (e.g., hepatitis, ischemic cardiovascular events) and Rare to Very Rare (e.g., Stevens-Johnson syndrome, Angioedema).

Serious Adverse Reactions and Safety Constraints

Official labeling highlights certain reactions due to their potential clinical significance. These include the documented association with a reduction in Bone Mineral Density (BMD), leading to an increased risk of fracture, and an observed increase in ischemic cardiovascular events. Furthermore, the medicine is officially contraindicated for use in premenopausal women, during pregnancy, and during lactation. The regulatory profile requires the monitoring of BMD and serum cholesterol levels during treatment, reflecting known safety considerations.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Anzol (Anastrozole) overdose indicates limited clinical experience, and a specific single dose resulting in life-threatening symptoms has not been established in clinical documentation. Furthermore, no clinically relevant adverse effects were observed following the administration of doses up to 60 mg in clinical trials, suggesting a lack of specific manifestations from overdosage alone.

Required Emergency Actions (Regulatory Mandate)
Seek immediate medical attention for any suspected overdose situation.
Contact emergency services immediately if the affected person has collapsed, had a seizure, has trouble breathing, or cannot be awakened.
Overdose Management and Observation
Antidote: There is no specific antidote known for Anastrozole overdosage.
Treatment: Management must be symptomatic and involve general supportive care. Treatment must also account for the possibility that multiple agents may have been taken.
Monitoring: Frequent monitoring of vital signs and close observation of the patient are indicated.
Supportive Measures: Vomiting may be induced if the patient is alert. Dialysis may also be considered by clinicians due to the low protein-binding characteristics of the drug.

This official profile emphasizes that the regulatory approach is focused on immediate emergency response and consistent supportive management. Treatment must be strictly symptomatic, as no specific reversal agent is available, and mandatory urgent help-seeking instructions are provided for generalized signs of severe patient distress.

Advertisements

Therapeutic Uses of Anzol (Anastrozole)

What Anzol (Anastrozole) Treats: Main Uses and Benefits

Anzol is commonly used for managing hormone receptor-positive (HR+) breast cancer in postmenopausal women, addressing conditions that present with systemic or localized discomfort.

The therapeutic contexts include supportive management after initial procedures, addressing advanced disease when management is first initiated, and risk management in specific populations. This therapy is relevant for easing symptoms that create noticeable physiological strain associated with tumor activity. Its use for long-term supportive management is relevant in contexts involving heightened systemic burden.

“Anzol is considered relevant in contexts where additional symptomatic support is needed to manage disease activity.”

This chronic therapy supports the patient during difficult episodes by easing distress and is used for managing the potential for disease return over time. This usage is applied across domains where additional symptomatic support is needed in situations involving risk management.


Quick Fact: Relief for Disease Progression
Anzol contributes to managing tumor growth in established malignancy, which assists with maintaining functional stability in advanced or metastatic settings.

Regulatory References

  1. National Cancer Institute (NCI)
Advertisements

Eligibility and Restrictions for Use

Eligibility Scope

The official population eligibility for Anastrozole is strictly defined by regulatory authorities and centers on hormonal status and specific health criteria.

Classification Population Group Constraint Basis
Contraindicated Premenopausal women Hormonal Status (Ineffective in this population)
Contraindicated Pregnant or Breastfeeding women Physiological State (Potential for fetal/infant harm)
Contraindicated Patients with known hypersensitivity Allergy (Risk of severe reaction)
Not Recommended Children and Adolescents (Pediatric) Age (Safety and efficacy not established)

Condition-Specific Eligibility Rules

Use is allowed primarily for postmenopausal women. While no general dosage adjustment is required for older adults (geriatric patients) or those with mild-to-moderate organ impairment, caution is formally advised in specific populations:

  • Hepatic Impairment: Caution is necessary for patients with moderate-to-severe liver disease.
  • Renal Impairment: Caution is necessary for patients with severe kidney disease.
  • Conditional Use: Patients with pre-existing ischemic heart disease or those at risk for osteoporosis require specific risk consideration and monitoring, respectively, as documented in regulatory warnings.

Connection to the Overall Eligibility Profile

Regulatory documents establish the primary eligibility requirement as postmenopausal status, leading to the absolute exclusion of premenopausal, pregnant, and breastfeeding women. The profile is further structured by specific regulatory warnings that enforce caution and monitoring for certain comorbid conditions or organ dysfunction, thereby defining the conditions under which the medicine may or may not be administered.

Advertisements

What should I know about interactions with other medicines?

The official regulatory profile for Anzol (Anastrozole) defines specific interaction restrictions based on established pharmacokinetic and pharmacodynamic data documented in government sources.

Formal Regulatory Prohibitions

Co-administration with Estrogen-Containing Therapies is strictly contraindicated. This restriction is based on pharmacodynamic antagonism, as estrogen products may diminish the pharmacological action of anastrozole. Similarly, concurrent use with Tamoxifen is also contraindicated. This prohibition stems from a pharmacokinetic interaction where co-administration results in a substantial reduction of anastrozole plasma concentration. Regulatory documents also state that use with LHRH analogues is not supported by available clinical data.


Absence of Clinically Significant Metabolic Alteration

Anastrozole has been tested for metabolic interactions with substances such as Warfarin and Antipyrine. Regulatory findings indicate that anastrozole does not significantly alter the pharmacokinetics or anticoagulant activity of Warfarin, nor does it affect the metabolism of Antipyrine. This confirms that the drug is unlikely to be a clinically relevant inhibitor or inducer of tested Cytochrome P450 pathways.


Administration and Special Populations

Administration can occur with or without food as food does not affect the extent of the drug's absorption. No mandatory timing separation rules are required for co-administered medicines. In patients with stable hepatic impairment, apparent oral clearance is lower, but plasma concentrations remain within the normal range. In severe renal impairment, the change in total clearance is deemed negligible.

Advertisements

Mechanism of Action

Molecular Domain: Competitive Aromatase Inhibition

Anastrozole acts as a non-steroidal competitive inhibitor that targets the Aromatase enzyme (CYP19A1). The molecule reversibly binds to the enzyme's active site, preventing the binding of the androgen precursor hormones. This targeted, non-destructive molecular blockade is highly selective, resulting in no inhibition of the synthesis of other steroids, such as cortisol or aldosterone.

Physiological Domain: Establishing Systemic Hypoestrogenism

The molecular blockade initiates a rapid mechanistic cascade by halting the conversion of androgens into estrone and estradiol in peripheral tissues (e.g., adipose tissue). This leads to a profound and sustained drop in circulating estrogen levels, establishing a state of hypoestrogenism. This physiological change is the direct outcome of the estrogen deprivation cascade.

Mechanistic Limitation: Overridden by Ovarian Function

The mechanism's effect is physiologically constrained by the endocrine feedback loop. In premenopausal individuals with intact ovarian function, the body's natural response to reduced peripheral estrogen is to increase the release of pituitary gonadotropins (LH and FSH). This hormonal increase stimulates the ovaries to increase estrogen production, overriding the peripheral block. This biological constraint defines the physiological context where the drug's mechanism results in sustained estrogen deprivation.

Advertisements

Dosage and Administration Information

Official Administration Guidelines

Anastrozole is strictly administered as a 1 mg oral tablet, defining a standardized approach to use. The regimen mandates the intake of one tablet once daily (qDay). The medicine can be taken with or without food, allowing for flexibility in daily timing.

Treatment duration is determined by the specific clinical context. For early-stage disease (adjuvant setting), the therapy is generally continued for a total duration of five years. For advanced or metastatic disease, the medicine is typically used on an ongoing basis until there is objective evidence of tumor progression.

Procedural and Population-Specific Instructions

Usage Constraint Official Requirement
Dose Consistency A 1 mg tablet is the required daily dose for all approved indications.
Missed Dose Protocol If a dose is missed, a double dose must never be taken.
Use Restriction Co-administration with Tamoxifen or estrogen-containing therapies is prohibited as it may interfere with its action.

Dosing Adjustments for Specific Populations

No dose adjustment is required for older adult (geriatric) patients. Similarly, no modification to the 1 mg dose is necessary for individuals with mild to moderate renal impairment or mild hepatic impairment. Anastrozole is generally not recommended for use in the pediatric population due to insufficient data for this group.

Advertisements

Recent Clinical Evidence

Anzol (Anastrozole): Recent Clinical Evidence

Anzol (Anastrozole) is a medication that belongs to the class of aromatase inhibitors. Clinical research primarily investigates its role in the management of hormone receptor-positive breast cancer in postmenopausal women.

Efficacy Data

Studies have explored Anastrozole's influence on reducing the risk of recurrence and improving disease-free survival rates in individuals with early-stage hormone receptor-positive breast cancer. Research has also examined its role in the extended adjuvant setting, which involves administration following an initial standard course of therapy.

Core Clinical Trials

Key research trials, such as the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial, have been foundational in evaluating Anastrozole. These large-scale, randomized studies compared Anastrozole against other standard endocrine therapies and/or placebo to assess long-term outcomes.

Trial Focus Primary Research Question Evaluated
Adjuvant Therapy Whether the drug influenced recurrence rates compared to tamoxifen or combination therapy.
Extended Adjuvant Therapy Whether continued use after standard treatment influenced long-term disease-free survival.

Safety and Tolerability

Clinical data has been collected to evaluate the drug's safety profile during long-term use. The most commonly reported potential side effects in trials relate to effects that may be associated with reduced estrogen levels, such as hot flashes, joint pain (arthralgia), and fatigue. Research continues to investigate the incidence of potential long-term risks, including bone mineral density loss and cardiovascular events, compared to other therapies.

Key Studies & References

  1. Anastrozole Prescribing Information (ARIMIDEX) - FDA/DailyMed
  2. NICE Guideline CG164: Familial breast cancer - Decision aid for postmenopausal women at high risk
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Anzol (Anastrozole) (FAQ)

Q: Is Anzol used for anything other than breast cancer?

The primary approved use for Anastrozole is the treatment of hormone receptor-positive breast cancer in women who are postmenopausal. However, official information notes that it is sometimes used for risk reduction in postmenopausal women with an increased risk profile for the disease.


Q: How quickly should I expect Anzol to start working?

According to pharmacokinetic studies, the active ingredient in Anzol is absorbed quickly, reaching its highest concentration in the blood within about two hours when taken on an empty stomach. The profound suppression of estrogen levels to a steady state is typically seen within seven days of starting treatment.


Q: Will Anzol affect my blood pressure?

Official product information states that high blood pressure, known as hypertension, has been reported as a side effect in clinical data. If this occurs, it is generally observed to develop gradually over a period of weeks or months after beginning the medication.


Q: Is weight gain a common side effect of Anzol?

Clinical data indicates that changes in weight have been reported by patients, with approximately 9% of individuals in some studies experiencing such effects. Weight gain is noted as a side effect that may develop after the initial weeks of treatment.


Q: What are the most common reasons a doctor might stop prescribing Anzol?

Studies show that the most common reason for patients to discontinue Anastrozole therapy is the occurrence of hot flashes. Treatment is also typically stopped if there is objective evidence that the tumor is progressing or if the patient experiences other adverse effects that are deemed unacceptable.


Q: Does Anzol interact with over-the-counter pain relievers like ibuprofen?

No formal drug interaction has been found between Anastrozole and ibuprofen specifically. However, regulatory information indicates that caution is necessary regarding the use of nonsteroidal anti-inflammatory drugs (NSAIDs), which includes ibuprofen, in patients who may have pre-existing heart failure or high blood pressure.


Q: Can Anzol be taken with supplements like Vitamin D or calcium?

Because Anzol is associated with a documented risk of reduced bone mineral density, health information often notes the importance of adequate intake of calcium and Vitamin D to help manage this known safety consideration.


Q: Is it okay to drink alcohol while using Anzol?

According to official information, there is no evidence suggesting that drinking alcohol causes a direct problem or drug interaction when taking Anzol. However, for some individuals, alcohol consumption may contribute to or worsen side effects such as hot flashes and skin redness.


Q: Do hot flashes from Anzol get better over time?

Reports based on patient experience indicate that menopausal symptoms like hot flashes and sweating often tend to improve and lessen in severity over the duration of treatment with the medication.


Q: Is there a generic version of Anzol available?

Yes, the active ingredient in Anzol, which is anastrozole, has been approved by government regulatory bodies, such as the FDA, for sale as a generic medication.


Q: If I stop taking Anzol, will the side effects go away immediately?

The speed at which side effects resolve can vary. Effects such as nausea and hot flashes may clear up within a few weeks of stopping the medication. However, some long-term safety considerations, such as changes in cholesterol levels or bone mineral density loss, may persist over a longer period.


Q: Can Anzol impact my ability to drive or operate machinery?

Official prescribing information states that the medicine has no or a negligible influence on a person's ability to drive or use heavy machinery. However, regulatory documents state that caution is advised if a patient experiences fatigue (asthenia) and sleepiness (somnolence).


Q: Is it normal for my hair to thin while taking Anzol?

Hair thinning, clinically known as alopecia, is listed in the official documents as a common side effect observed in clinical trials. This effect is usually reported to be mild and does not typically result in complete hair loss.


Q: Can Anzol interfere with birth control methods?

The use of medications that contain estrogen is formally contraindicated (prohibited) with Anzol because the estrogen can counteract the medicine's primary action. Regulatory documentation states that any birth control method containing estrogen is contraindicated (prohibited) for concurrent use.


Q: Is there a risk of developing blood clots while on Anzol?

Clinical trials have documented an increased incidence of venous thromboembolic events (VTEs), which include blood clots, in some patient groups receiving Anastrozole when compared to alternative endocrine therapies. This indicates a known risk documented in the safety profile.


Q: Can Anzol be crushed or split if it's hard to swallow?

The medication is only available as a solid oral tablet, and there is no soluble or liquid formulation. Crushing or dispersing the tablet is generally considered an unlicensed use of the medicine, meaning it is not supported by standard administration guidelines.


Q: What is the typical timeframe for follow-up appointments when taking Anzol?

Regulatory monitoring guidelines, which address the known risk of osteoporosis, state that assessing bone mineral density before starting treatment and checking it at regular intervals throughout therapy is required.


Q: Are there any lifestyle changes that can help with Anzol side effects?

Clinical management strategies, cited in medical literature, suggest that incorporating exercise and managing body weight has been studied as a strategy to address some of the reported musculoskeletal side effects. Counseling on ways to manage vaginal symptoms is also recommended.


Q: Can Anzol cause changes to vision?

Official clinical data has reported that cataract, a condition affecting the lens of the eye, has been observed as an ophthalmic (eye-related) side effect.

Advertisements

How should Anzol (Anastrozole) be stored and disposed of?

Storage and Disposal of Anastrozole

Anastrozole tablets must be stored at Controlled Room Temperature, which is officially defined as 20 C to 25 C (68 F to 77 F). Temporary temperature excursions between 15 C and 30 C are permitted, but freezing should be avoided.

Storage must occur in the original container and in a dry place to maintain the product's stability and protect it from moisture. A mandatory requirement is to keep the medicine out of the sight and reach of children to prevent accidental ingestion.

For disposal, the regulatory instruction is to not throw away unused or expired tablets in the household trash or flush them down the wastewater system. Disposal must instead follow local regulatory requirements, typically by returning the product to a pharmacist or a designated medicine collection site.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Anzol (Anastrozole) found in:

A-Z Index: